ATE281451T1 - Imidazolderivate und deren verwendung als raf kinase inhibitoren - Google Patents
Imidazolderivate und deren verwendung als raf kinase inhibitorenInfo
- Publication number
- ATE281451T1 ATE281451T1 AT00977660T AT00977660T ATE281451T1 AT E281451 T1 ATE281451 T1 AT E281451T1 AT 00977660 T AT00977660 T AT 00977660T AT 00977660 T AT00977660 T AT 00977660T AT E281451 T1 ATE281451 T1 AT E281451T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase inhibitors
- imidazole derivatives
- raf kinase
- occurred
- excessive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16689599P | 1999-11-22 | 1999-11-22 | |
US16681499P | 1999-11-22 | 1999-11-22 | |
US16688599P | 1999-11-22 | 1999-11-22 | |
US16688699P | 1999-11-22 | 1999-11-22 | |
PCT/GB2000/004413 WO2001038324A2 (en) | 1999-11-22 | 2000-11-20 | Imidazole derivatives and their use as raf kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE281451T1 true ATE281451T1 (de) | 2004-11-15 |
Family
ID=27496721
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00978816T ATE382044T1 (de) | 1999-11-22 | 2000-11-20 | Imidazol- derivate |
AT00977660T ATE281451T1 (de) | 1999-11-22 | 2000-11-20 | Imidazolderivate und deren verwendung als raf kinase inhibitoren |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00978816T ATE382044T1 (de) | 1999-11-22 | 2000-11-20 | Imidazol- derivate |
Country Status (21)
Country | Link |
---|---|
US (3) | US7189745B1 (de) |
EP (2) | EP1232153B1 (de) |
JP (2) | JP2003514906A (de) |
KR (1) | KR20020050294A (de) |
CN (1) | CN1543346A (de) |
AT (2) | ATE382044T1 (de) |
AU (2) | AU1529901A (de) |
BR (1) | BR0015532A (de) |
CA (1) | CA2395564A1 (de) |
CZ (1) | CZ20021746A3 (de) |
DE (2) | DE60015594T2 (de) |
ES (2) | ES2228629T3 (de) |
HK (1) | HK1050190A1 (de) |
HU (1) | HUP0203403A3 (de) |
IL (2) | IL149150A0 (de) |
MX (1) | MXPA02005106A (de) |
NO (1) | NO20022318L (de) |
NZ (1) | NZ518032A (de) |
PL (1) | PL355912A1 (de) |
TR (1) | TR200201364T2 (de) |
WO (2) | WO2001038324A2 (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
DE60015594T2 (de) | 1999-11-22 | 2005-10-27 | Smithkline Beecham P.L.C., Brentford | Imidazolderivate und deren verwendung als raf kinase inhibitoren |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
JP4217480B2 (ja) * | 2000-11-20 | 2009-02-04 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
US7446106B2 (en) | 2001-09-05 | 2008-11-04 | Smithkline Beecham Plc | Pyridylfurans and pyrroles as Raf kinase inhibitors |
US7375105B2 (en) | 2001-09-05 | 2008-05-20 | Smithkline Beecham P.L.C. | Pyridine substituted furan derivatives as Raf kinase inhibitors |
GB0121488D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
WO2003076434A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
AU2003246972A1 (en) | 2002-08-06 | 2004-02-23 | Astrazeneca Ab | Condensed pyridines and pyrimidines with tie2 (tek) activity |
AU2003262911A1 (en) | 2002-08-29 | 2004-03-19 | Scios Inc. | Methods of promoting osteogenesis |
WO2004037789A2 (en) | 2002-10-24 | 2004-05-06 | Merck Patent Gmbh | Methylene urea derivatives as raf-kinase inhibitors |
EP2426122A1 (de) * | 2002-10-24 | 2012-03-07 | Merck Patent GmbH | Methylenharnstoffderivate als Inhibitoren von RAF Kinase |
GB0230089D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
US7361669B2 (en) | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
CA2540518A1 (en) * | 2003-10-02 | 2005-04-07 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2005063716A1 (en) | 2003-12-22 | 2005-07-14 | Janssen Pharmaceutica, N.V. | Imidazoles and their use cck-1 receptor modulators |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
CA2557359A1 (en) * | 2004-02-26 | 2005-09-09 | Hans-Peter Buchstaller | Semicarbazide derivatives as kinase inhibitors |
EP1676574A3 (de) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten |
WO2007016286A1 (en) * | 2005-07-28 | 2007-02-08 | Janssen Pharmaceutica N.V. | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine |
CA2623374A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
AU2007251282A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
EP2170887A2 (de) | 2007-06-07 | 2010-04-07 | Amgen Inc. | Heterocyclische verbindungen als modulatoren von raf-kinase |
WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2274300A2 (de) * | 2008-03-21 | 2011-01-19 | Novartis AG | Neue heterocyclische verbindungen und anwendungen davon |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
WO2011044414A1 (en) * | 2009-10-08 | 2011-04-14 | Glaxosmithkline Llc | Combination |
ME03497B (de) * | 2009-10-16 | 2020-04-20 | Novartis Ag | Kombination enthaltend ein MEK Inhibitor und ein B-raf Inhibitor |
US20120270251A1 (en) * | 2009-12-22 | 2012-10-25 | Csir | Inhibition of the activity of kinase and synthetase enzymes |
CN103159735B (zh) * | 2011-12-10 | 2015-12-09 | 通化济达医药有限公司 | 取代的咪唑激酶抑制剂 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
US10605785B2 (en) * | 2017-06-07 | 2020-03-31 | General Electric Company | Sensor system and method |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
US3940486A (en) | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
US4447413A (en) * | 1980-05-08 | 1984-05-08 | Aviation Chemical, Inc. | Drift influencing composition |
US4348404A (en) | 1980-07-21 | 1982-09-07 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines |
CA1175431A (en) | 1980-07-25 | 1984-10-02 | Alfred Sallmann | Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use |
US5166214A (en) | 1988-12-05 | 1992-11-24 | Du Pont Merck Pharmaceutical Company | Use of imidazoles for the treatment of atherosclerosis |
US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
US5179117A (en) | 1991-12-20 | 1993-01-12 | Du Pont Merck Pharmaceutical Company | Antihypercholesterolemic 2-substituted imidazoles |
US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
US5310748A (en) | 1992-05-11 | 1994-05-10 | The Du Pont Merck Pharmaceutical Company | Imidazoles for the treatment of atherosclerosis |
DE69401486T2 (de) | 1993-11-12 | 1997-04-30 | Ishihara Sangyo Kaisha | Verfahren zur Herstellung 2-cyanoimidazol Derivate |
US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
EP0833664A1 (de) | 1995-06-12 | 1998-04-08 | G.D. SEARLE & CO. | Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
JP2000507545A (ja) | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Cns損傷についての新規な治療 |
JP2000504023A (ja) | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
DE69733135T2 (de) | 1996-06-10 | 2006-03-02 | Merck & Co., Inc. | Substituierte imidazole mit cytokinin-inhibirender wirkung |
RU2239429C2 (ru) | 1996-10-15 | 2004-11-10 | Джи. Ди. Сирл Энд Ко. | Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии |
JP4380803B2 (ja) | 1997-06-12 | 2009-12-09 | アベンテイス・フアルマ・リミテツド | イミダゾリル−環式アセタール |
GB9713726D0 (en) * | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
US6040320A (en) | 1997-06-30 | 2000-03-21 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
AU9648098A (en) | 1997-10-27 | 1999-05-17 | Takeda Chemical Industries Ltd. | Adenosine a3 receptor antagonists |
KR100704977B1 (ko) * | 1997-12-22 | 2007-04-09 | 바이엘 코포레이션 | 대칭성 및 비대칭성 치환디페닐우레아를 이용한 raf키나제의 저해 |
AU765412B2 (en) | 1997-12-22 | 2003-09-18 | Bayer Healthcare Llc | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
AU760527C (en) | 1998-05-22 | 2004-05-06 | Smithkline Beecham Corporation | Novel 2-alkyl substituted imidazole compounds |
AU4395399A (en) | 1998-07-02 | 2000-01-24 | Sankyo Company Limited | Five-membered heteroaryl compounds |
US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
WO2000026209A1 (en) | 1998-11-03 | 2000-05-11 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
AU2164300A (en) | 1998-12-04 | 2000-06-26 | N.V. Organon | Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin |
AU4556800A (en) | 1999-04-27 | 2000-11-10 | Smithkline Beecham Plc | Novel treatment |
DE60015594T2 (de) | 1999-11-22 | 2005-10-27 | Smithkline Beecham P.L.C., Brentford | Imidazolderivate und deren verwendung als raf kinase inhibitoren |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
ES2218391T3 (es) | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
WO2002024680A1 (en) | 2000-09-21 | 2002-03-28 | Smithkline Beecham P.L.C. | Imidazole derivatives as raf kinase inhibitors |
JP4217480B2 (ja) | 2000-11-20 | 2009-02-04 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
US7446106B2 (en) | 2001-09-05 | 2008-11-04 | Smithkline Beecham Plc | Pyridylfurans and pyrroles as Raf kinase inhibitors |
US20040192689A1 (en) | 2001-09-05 | 2004-09-30 | Dean David Kenneth | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
US7375105B2 (en) | 2001-09-05 | 2008-05-20 | Smithkline Beecham P.L.C. | Pyridine substituted furan derivatives as Raf kinase inhibitors |
GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
-
2000
- 2000-11-20 DE DE60015594T patent/DE60015594T2/de not_active Expired - Fee Related
- 2000-11-20 EP EP00977660A patent/EP1232153B1/de not_active Expired - Lifetime
- 2000-11-20 US US10/130,018 patent/US7189745B1/en not_active Expired - Fee Related
- 2000-11-20 TR TR2002/01364T patent/TR200201364T2/xx unknown
- 2000-11-20 US US10/130,019 patent/US7026336B1/en not_active Expired - Fee Related
- 2000-11-20 ES ES00977660T patent/ES2228629T3/es not_active Expired - Lifetime
- 2000-11-20 WO PCT/GB2000/004413 patent/WO2001038324A2/en active IP Right Grant
- 2000-11-20 BR BR0015532-2A patent/BR0015532A/pt not_active Application Discontinuation
- 2000-11-20 MX MXPA02005106A patent/MXPA02005106A/es unknown
- 2000-11-20 JP JP2001540087A patent/JP2003514906A/ja not_active Withdrawn
- 2000-11-20 WO PCT/US2000/031791 patent/WO2001037835A1/en active Search and Examination
- 2000-11-20 NZ NZ518032A patent/NZ518032A/en unknown
- 2000-11-20 EP EP00978816A patent/EP1233769B1/de not_active Expired - Lifetime
- 2000-11-20 AT AT00978816T patent/ATE382044T1/de not_active IP Right Cessation
- 2000-11-20 PL PL00355912A patent/PL355912A1/xx not_active Application Discontinuation
- 2000-11-20 AT AT00977660T patent/ATE281451T1/de not_active IP Right Cessation
- 2000-11-20 CZ CZ20021746A patent/CZ20021746A3/cs unknown
- 2000-11-20 CN CNA008159491A patent/CN1543346A/zh active Pending
- 2000-11-20 AU AU15299/01A patent/AU1529901A/en not_active Abandoned
- 2000-11-20 CA CA002395564A patent/CA2395564A1/en not_active Abandoned
- 2000-11-20 DE DE60037597T patent/DE60037597T2/de not_active Expired - Fee Related
- 2000-11-20 KR KR1020027006476A patent/KR20020050294A/ko not_active Application Discontinuation
- 2000-11-20 IL IL14915000A patent/IL149150A0/xx active IP Right Grant
- 2000-11-20 AU AU16236/01A patent/AU1623601A/en not_active Abandoned
- 2000-11-20 JP JP2001539450A patent/JP2003514860A/ja active Pending
- 2000-11-20 ES ES00978816T patent/ES2298165T3/es not_active Expired - Lifetime
- 2000-11-20 HU HU0203403A patent/HUP0203403A3/hu unknown
-
2002
- 2002-04-15 IL IL149150A patent/IL149150A/en not_active IP Right Cessation
- 2002-05-15 NO NO20022318A patent/NO20022318L/no not_active Application Discontinuation
-
2003
- 2003-01-29 HK HK03100744.6A patent/HK1050190A1/zh unknown
-
2006
- 2006-09-19 US US11/533,034 patent/US20070010534A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE281451T1 (de) | Imidazolderivate und deren verwendung als raf kinase inhibitoren | |
ATE250577T1 (de) | Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten | |
ATE300529T1 (de) | Imidazolderivate als raf-kinase-inhibitoren | |
NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
HRP20050059B8 (hr) | Novi inhibitori kinaza | |
HK1054039A1 (en) | Substituded beta-carbolines | |
NO20021358D0 (no) | Alkylendiamin-substituerte heterocykler | |
NZ512096A (en) | Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors | |
TR200200928T2 (tr) | 2-pirazolin-5-on terkipleri | |
NO20071574L (no) | Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander. | |
DE69723863D1 (de) | Chinoline und deren therapeutische verwendung | |
ATE365730T1 (de) | Neuartige verbindungen | |
ATE369860T1 (de) | Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie | |
NO963706L (no) | Benzenkondenserte heterosykliske derivater og deres anvendelse | |
ES2249309T3 (es) | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. | |
DE60103856D1 (de) | Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität | |
ATE277010T1 (de) | Bis-indolederivate und ihre verwendung als entzündungshemmende mittel | |
ATE336489T1 (de) | Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren | |
EP1372648A4 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
DE50003307D1 (de) | Arylsulfonamid-substituierte benzimidazolderivate ihre verwendung als tryptase-inhibitoren | |
ATE236887T1 (de) | Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |